
|Articles|February 1, 2005
Modified implant technique may minimize problems with miniature shunt
New Orleans—The ExPRESS miniature glaucoma shunt (Optonol Ltd., Neve Ilan, Israel; marketed by CIBA Vision, Duluth, GA), originally intended to be placed through the limbus and under a conjunctival flap, produced significant IOP lowering yet an unacceptable high rate of complications. So researchers are now investigating placement of the device under a scleral flap, according to Marlene R. Moster, MD.
Advertisement
Newsletter
Don’t miss out—get Ophthalmology Times updates on the latest clinical advancements and expert interviews, straight to your inbox.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Ophthalmology Times - Clinical Insights for Eye Specialists
1
FDA issues Complete Response Letter to Sydnexis for SYD-101 pediatric myopia treatment
2
STAAR postpones Alcon merger vote, Broadwood calls for removal of board members
3
Novel therapy for incision-free keratoconus: Q&A with Gloria B. Chiu, OD, FAAO, FSLS
4
Nanoscope Therapeutics releases positive 3-year follow-up data from REMAIN study
5

















































.png)


